Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 3Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiotherapy 8Doxorubicin 8Nivolumab 7Immunoglobulin G 6Disulfides 6Cisplatin 6Biopsy 6Radiation 5Platinum 5Paclitaxel 5Cytarabine 5Bevacizumab 51,2-diaminocyclohexaneplatinum II citrate 5atezolizumab 4Vincristine 4Taxes 4Prednisone 4Methotrexate 4Daunorubicin 4Cyclophosphamide 4Cetuximab 4Carboplatin 4prednylidene 3merphos 3liposomal doxorubicin 3deltacortene 3Temozolomide 3Radiotherapy, Intensity-Modulated 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NIH × Colony-Stimulating Factors × Clear all
NCT02339571 2026-05-29

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
600 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡